Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Sensei Biotherapeutics, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
SNSE
Nasdaq
2834
www.senseibio.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Sensei Biotherapeutics, Inc.
What Makes Sensei Biotherapeutics (SNSE) a New Buy Stock
- Feb 6th, 2025 5:00 pm
Sensei Biotherapeutics to Participate in Oppenheimer’s 35th Annual Healthcare Life Sciences Conference
- Feb 4th, 2025 12:30 pm
Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones
- Jan 8th, 2025 12:30 pm
Sensei Biotherapeutics to Participate in Citi’s 2024 Global Healthcare Conference
- Nov 27th, 2024 9:05 pm
Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
- Nov 14th, 2024 12:30 pm
Sensei Biotherapeutics to Present at Two Upcoming Scientific Conferences
- Oct 29th, 2024 11:30 am
3 US Penny Stocks To Monitor In October 2024
- Oct 22nd, 2024 7:08 pm
Sensei Biotherapeutics to Present Preclinical Data on SNS-103 at the CRI-ENCI Eighth International Immunotherapy Conference
- Sep 4th, 2024 8:05 pm
Sensei Biotherapeutics to Present at Upcoming Conferences
- Sep 4th, 2024 11:30 am
Sensei Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
- Aug 6th, 2024 11:30 am
Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference
- May 30th, 2024 11:30 am
Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101
- May 23rd, 2024 9:10 pm
Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
- May 9th, 2024 11:30 am
Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting
- Apr 24th, 2024 8:05 pm
Sensei Biotherapeutics to Participate in Canaccord Genuity’s Horizons in Oncology Virtual Conference
- Apr 9th, 2024 11:30 am
Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment
- Apr 4th, 2024 8:05 pm
Sensei Biotherapeutics to Participate in the 3rd Annual VISTA Symposium
- Mar 22nd, 2024 11:30 am
Sensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific Conferences
- Mar 6th, 2024 12:30 pm
Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights
- Feb 28th, 2024 12:30 pm
Scroll